AdvanceAD-Tx
OverviewScientific EvidenceOrder Process & Results
Order process and results

Learn how to order AdvanceAD-Tx

‍

AdvanceAD-Tx is a non-invasive gene expression profile test designed to help guide systemic treatment decisions in patients with moderate-to-severe atopic dermatitis.

‍

Ordering AdvanceAD-Tx

Ordering
Testing process (Logistics)
results
Patient access (INSURANCE)

Ordering AdvanceAD-Tx

If you are interested in ordering a test, please complete the form below.

Connect with a representative

Testing process

The AdvanceAD-Tx test uses a simple, non-invasive skin scraping that can be collected in the dermatology office with a test kit.  The test kit along with two samples, the completed test request form, and signed clinic note are shipped directly to Castle where the sample is processed.

Watch to learn more about AdvanceAD-Tx Sample Collection

Report results

Castle performs the test in a CAP-accredited and CLIA-certified laboratory and delivers the report within 7-10 days from receipt of sample.  The AdvanceAD-Tx test provides a result of either:
- JAK Inhibitor Responder Profile
- Th2 Molecular Profile

Download a Sample Report

Patient access

Castle Biosciences is committed to providing high-quality molecular testing to all patients. We do not want financial concerns to be a barrier to patients accessing critical healthcare information. We intend to work with all insurance providers, including Medicare, Medicaid, commercial insurers, and Veterans Affairs (VA), to secure payment coverage for our testing.

For those who may need additional assistance for their Castle test, we offer a comprehensive patient assistance program to all patients.

If you have any questions, please contact us by calling 866-788-9007, option 3 or send an email.

Understanding the AdvanceAD-Tx Results

AdvanceAD-Tx distinguishes between two biologically distinct molecular subtypes of atopic dermatitis—something not visible through clinical features alone.

JAK Inhibitor Responder Profile Result

Patients with this profile who are treated with a JAK inhibitor compared to patients who are treated with Th2 therapy have a higher likelihood of acheiving superior response: 

      1. Increased likelihood of achieving EASI-90/vIGA-AD 0/BSA 0% by 3 months
      2. Faster time to achieving EASI-90
      3. More likely to remain flare-free
      4. Improved quality of life (DLQI 0)

‍

Th2 Molecular Profile Result

‍

Patients with this profile show no meaningful difference in the likelihood of achieving comparable response with either a JAK inhibitor or a Th2-targeted therapy by 3 months:

  1. Similar EASI-90/vIGA-AD, itch, & flare result by 3 months
  2. Similar time to acheiving EASI-90 response

‍